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A STUDY of and search for anti-tumour drugs among halogenoalkylamines
started at the beginning of 1947 in the laboratory of Experimental Therapy of
Cancer and inthe clinic ofthe Institute ofOncology, Academy ofMedical Sciences,
U.S.S.R., inLeningrad, together with Professor V. G. Nemetz (Professor ofChemis-
try at the Technological Institute in Leningrad). Experimental and clinical
investigations were carried on simultaneously with di-(2-chloroethyl) methylamine
which we named Embichin.
The experimental study of Zhdanov (1953) on rabbits showed that the effect
of Embichin upon the blood system depended to a great extent on the intervals
between the injections of this substance (Fig. 1 and 2). On the basis ofthese data
a new method oftherapeutic use ofEmbichin was worked out by me, together with
the doctors ofthe clinic (Larionov, 1951) which differed from the one proposed by
the American authors. (Jacobson et al., 1946).
Instead of 4 to 5 daily injections of doses of 0-1 mg. per kg. body-weight, we
made from 10 to 20 injections at a dose of 5 to 6 mg. three times a week. This
prolonged method achieves the same therapeutic effect, whilst to a certain extent
sparing the haemopoietic system and its reaction to the drug.
The essential criterion for the determination ofthe number ofinjections for the
individual patient was the white cell count. We stopped the injections ofEmbichin
in Hodgkin's disease when the number of leucocytes had fallen to 2500-3000.
Under these conditions the maximum therapeutic effect is attained and the ability
of the haemopoietic system to recover its normal function is maintained for 3 to
4 weeks.
This method of treatment of Hodgkin's disease and leukemia with Enmbichin
has been widely used since 1949 in the medical institutions of the U.S.S.R. Our
experience is that this method makes it possible to get immediate and long-lasting
results in the treatment of Hodgkin's disease in the relatively early stages, which
are definitely no worse than those achieved by X-ray therapy. We consider it
valuable to apply chloroethylamine therapy to patients in the early stages of the
disease who have had no previous treatment, as well as to patients with advanced
Hodgkin's disease for whom X-ray therapy is not longer applicable.
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FIG. 1.-The action of Embichin on the composition of leucocytes in the blood of rabbits
receiving daily injections in doses of 0*5 mg./kg.
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FIG. 2.-The action of Embichin with injections in similar doses,
but at 48-hourly intervals.
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The best results are obtained by means of a rational combination of chemo-
therapy and X-ray therapy. We begin the treatment with chemotherapy andthen,
ifnecessary, follow it up with X-ray therapy alone, inthose cases where the nodules
have not completely regressed.
Along with this work we conducted a study of a series of homologues and
analogues of Embichin with the aim of finding those compounds which would be
thebesttolerated andhaveleast depressive actionuponbone-marrow haemopoiesis.
At first the compounds in which two valencies of nitrogen were occupied by two
chloroethyl groups and the third by ethyl, isopropyl, butyl or 2-chloropropyl were
synthesised and studied. (The last compound was designated as EmbichinNo. 7.)
2-Chloroethyl-2-chloropropylmethylamine (designated as Embichin No. 11) and
the di- and tri-2-chloropropylamines were also studied.
It became clear that among these compounds, Embichin No. 7 (at first studied
experimentally by S. A. Papojan) and Embichin No. 11 (studied by G. L. Zhdanov,
Z. P. Sofyina and SH. M. Timerbulatova) were the more effective.
Embichin No. 7, i.e. 2-chloropropyl-di(2-chloroethyl)amine hydrochloride
subsequently found practical application. Its action on the animal and human
bone marrow is not so severe as on the lymphoid organs. It is much better
tolerated by the patients (especially when dissolved in Ringer's solution) possessing
a less pronounced side effect upon the gastro-intestinal tract than Embichin.
This new drug, called Novoembichin, has been used in the medical institutions
in the U.S.S.R. since 1952, to whom it is supplied by the chemopharmaceutical
industry. Clinically, Novoembichin has replaced Embichin since it possessed all
the therapeutic properties of Embichin, whilst exerting milder effect upon the
bone marrow and very seldom causing vomiting in patients.
The single doseofNovoembichin ishigherthanthatofEmbichin. ForHodgkin's
disease it is from 9 to 10 mg. for adults; for lymphatic leukemia it is 8 mg., for
myelogenous leukemia it is 10 mg. The method of application is the same as that
of Embichin, the drug being injected intravenously in 20 ml. of Ringer's solution
three times a week. The total course is from 8 to 16 injections.
The need for a therapeutic drug possessing the same activity as Embichin,
yet which could be used orally, led us to study the compounds of the aromatic
series which are practically insoluble in water. The British investigators Haddow,
Kon and Ross (1948) independently followed a similar path. However, we selected
the derivative of aniline rather than of naphthylamine. This drug, i.e. N: N-di-
(2-chloroethyl) aniline hydrochloride, called Lymphochin, has been studied in
detail by animal experiments in the laboratory ofthe Department of Experimental
Chemotherapy ofthe Institute ofExperimental Pathology and Therapy ofCancer,
Academy of Medical Sciences, U.S.S.R. (Moscow), by my co-workers A. Y.
Krashilina and V. P. Konoplev. We have also studied the corresponding bromo-
derivative (I. G. Spasskaya).
These compounds when administered orally indaily doses of5 mg./kg. produced
changes in the haemopoietic system of rabbits without injuring the mucous
membrane of the gastro-intestinal tract. These changes closely resembled those
caused by Novoembichin, but the effect upon the lymphatic system was greater.
The crossing of the curves ofleucocytes in the blood-the decrease in the number
of leucocytes and the increase of pseudoeosinophiles (in absolute figures)-was
observed in some animals (Fig. 3). Lymphochin used at the same dose level did
-not exert any harmful effect upon the renal function (E. A. Eard).
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These findings enabled us to proceed with the clinical investigations ofLympho-
chin inthetreatment ofHodgkin's disease, whichwas carriedout byG. V. Kruglova,
in the clinic of the same Institute.
It became evident that when administered orally in daily doses of 04 g.,
Lymphochin seldom caused vomiting or nausea in patients and some tolerated it
well. According to our findings, as distinct from those of the British investigators
(Haddow, Kon and Ross, 1948), Lymphochin in the doses mentioned above did
not induce a marked depression of the bone marrow. Nevertheless, its effect in
Hodgkin's disease appeared to be less than that of Embichin and Novoembichin,
and its clinical application was dropped, in favour of new drugs which were then
being produced.
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FIG. 3.-The action of Lymphochin on the composition of leucocytes in the
blood of rabbits receiving intermittent doses of 5 mg./kg.
The above mentioned drugs are used exclusively for the treatment of diseases
of the haemopoietic system, such as Hodgkin's disease, chronic leukemia, poly-
cythemia and also for some malignant tumours of lymphoid organs, particularly
lymphosarcomas and undifferentiated tumours of the lymphatic apparatus of the
throat. The successful treatment of the latter condition was carried out by
Professor N. A. Karpov and J. N. Smirnova in Leningiad.
Thepalliativeeffect oftreating bronchogenic carcinomapatients with Embichin
was reported in the literature (Boyland, Clegg, Koller, Rhoden and Warwick,
1948). We also observed it but in our opinion it is ofno great practical significance.
We have found that the use of Embichin or Novoembichin leads to the regression
of breast cancer metastases in cervical and axillary lymphatic nodules (Larionov,
Kholdin and Litvinova, 1953). We followed up a few patients for three years after
such treatment and they had no relapseswhatsoever. In one patient theregression
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of a metastasis in the sternum took place. However, the virtual ineffectiveness
of the chloroethylamines towards typical malignant tumours made us search for
ways of increasing their effectiveness.
With this aim in view a great deal of work on the synthesis and investigation of
new derivatives of 2-chloroethylamines was carried out under my direction in the
Department of Experimental Chemotherapy, Institute ofExperimental Pathology
and Therapy of Cancer, (Director Prof. N. N. Blokhin), Academy of Medical
Sciences, Moscow, U.S.S.R.
The principle ofthis work was to attempt to increase the anti-tumourproperties
of the chloroethylamines by adding them as active chemical groups to biologically
significant compounds or their components.
From a consideration, particularly of the intensive synthesis of protein and
nucleic acid in tumours and also their intensive tissue metabolism in general,
some essentialaminoacids, especiallyphenylalanine, were chosen as suchbiologically
significant compounds. Since heterocycles are the constituents of nucleic acids,
ofsome coferments and vitamins, compounds such as pyrimidine, purine, pyridine,
thiazole, benzimidazole, were also selected for preparation of the 2-chloroethyl-
amino derivatives. It was assumed that amino acids and possibly the natural
heterocycles might serve as " conductors " assisting the transport of chloroethyl-
amine groups into tumour tissues. Another possibility not to be excluded was that
the 2-chloroethylamino-derivatives of the natural compounds might to some
extent play the role of antimetabolites in the intensive protein and nucleic acid
metabolism of tumour tissues. The synthesis of the chloroethylamino-derivative
of pyridoxine was achieved by Stock and his collaborators (Stock et al. 1951),
but clinical trials were stopped because of the depressant action this drug had on
haemopoiesis.
The studyoftheactivityofthedi(2-chloroethyl)amino-derivativesofpyrimidine,
pyridine, thiazole, benzimidazole and phenylalanine showed that they actually
possessed greater anti-tumour activity than Embichin. Different susbtances were
tested against sarcoma 45 and M-1 of rats and against a number oftransplantable
mouse tumours. The aim ofthese tests was to establish the comparative efficiency
of these drugs.
Whilst the inhibition of Sarcoma 45 by Embichin never exceeded 20 per cent,
the inhibition caused by the chloroethylamino-derivatives ofthe above mentioned
heterocycles and amino acids was from 60 to 100 per cent, and even more striking,
these drugs caused the regression of some or all tumours. It should be noted that
the administering of the drugs began when the tumours had already developed
and could be measured and weighed.
The comparative studies showed that 2,6-dihydroxy-4-methyl-5-di-(2-chloro-
ethyl)aminopyrimidine (the drug called Dopan), synthesized by V. G. Nemetz
and investigated by our assistant G. N. Platonova had the strongest anti-tumour
action out of all the investigated heterocyclic derivatives. The drug does not
dissolve well in water and is administered orally.
In daily therapeutic doses of 0-3 mg./kg. Dopan causes the gradual regression
of tumours (Sarcoma 45) weighing 1-4 g. (i.e. from 1 to 4 per cent of the body
weight) in from 90 to 100 per cent of rats (Fig. 4, 5, 6).
Dopan has a strong anti-tumour action and at the same timedepresses haemo-
poiesis, especially in the bone marrow. Thus, the administration of the drug to
rabbits in daily doses of 0 3 mg./kg. decreases the number of leucocytes in the
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blood by the seventh or eighth day to 3-4000/c.mm.; this decrease takes place
chiefly because of the fall in pseudoeosinophiles.
The clinical trials of Dopan carried out recently at the Institute have already
shown that the drug has a marked therapeutic effect in Hodgkin's disease, myelo-
genic leukemia and reticulo-sarcoma. The drug is administered orally in a dose of
8 to 10 mg. twice weekly. It has almost no side effects upon the gastro-intestinal
tract. Its action upon haemopoiesis closely resembles that of Embichin.
We have already reported the biological studies of sarcolysine, DL-p-di(2-
chloroethyl)aminophenylalanine, (Larionov et al., 1955). This drug which was
synthesised independently by Bergel and Stock (1954) and studied experimentally
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FIG. 4-Curve sliowing changes in the average diameter of tumours (sarcoma 45) treated with
Dopan. C, curve of control rat tumour. Lower curves show experiments with treatment
beginning on the 7th and 12th days after transplantation. 0*2 g. and 4 g. are the corres-
ponding mean weights of the tumours at these times.
by Haddow, has now hadabout a year's clinical trial inthe clinic ofthe Institute by
L. I. Chebotareva under the direction of Professor N. N. Blokhin (with my partici-
pation). It appeared that some human malignant tumours were very sensitive to
sarcolysine. They are: undifferentiated tumours of testes (seminomas), reticulo-
sarcomas, angioendotheliomas and Ewing's tumour. Sarcolysine did not show any
effect upon bone sarcomas, fusiform-cell and polymorphic-cell sarcomas of soft
tissues.
The drug was injected intravenously in saline solution in doses of from 50 to
25 mg. once weekly in total of from 4 to 6 times under blood count control. The
drug is also effective when administered orally in tablets. The metastases of
seminomas into retroperitoneal and peripheral lymph nodes even of large size
regressed after 3 to 5 injections of sarcolysine. Two patients (one with cured
metastasis of seminomas on the neck and one with retroperitoneal lymph nodules)
were followed up by us for 11 and 8 months respectively and have had no relapse.
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With incomplete regression, especially in reticulosarcoma, relapses were observed.
With correct dosage the depression of haemopoiesis is moderate and normal blood
content is re-established in from 3 to 4 weeks. With the dosage higher than
optimal some patients showed a sharp depression ofhaemopoiesis down to agranu-
locytosis accompanied by high fever. Clinical studies are still under way.
Thus, systematic work on synthesis and application of chloroethylamine
derivatives of natural heterocycles and amino acids has led to the creation of new
therapeutic drugs ofanti-tumour action. It is probable that further investigations
in this field can lead to further successes.
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EXPLANATION OF PLATE.
FIG. 5.-Section of the untreated rat sarcoma 45. Haemotoxylin and eosin. x 155.
FIG. 6.-Section through the small nodule remaining after regression of the tumour following
the use ofDopan. The few sarcoma cells are evidently the tumour stroma. Haemotoxylin
and eosin. x 155.BRITISH JOURNAL OF CANCER.
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